ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerDavid Planchard, Dariusz M. Kowalski, С. В. Орлов et al.|Annals of Oncology|2020Cited by 164
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatmentDariusz M. Kowalski, David Planchard, Niels Reinmuth et al.|Annals of Oncology|2018Cited by 17
576P The synergistic anticancer effect of PLAG on the PD-1 immune checkpoint inhibitor in the LLC-1 murine lung carcinoma syngeneic modelG.T. Kim, Jong Woo Kim, Sohye Yoon et al.|Annals of Oncology|2020Cited by 0